New hope for hepatitis b patients with normal ALT: TMF drug trial underway

NCT ID NCT05797714

Ongoing Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called Tenofovir Amibufenamide (TMF) in 200 adults with chronic hepatitis B who have normal liver enzyme levels (ALT). The goal is to see if TMF can lower the virus to undetectable levels and possibly clear the hepatitis B surface antigen. Participants are randomly assigned to receive TMF or no treatment, and results are measured after 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tenofovir Amibufenamide (TMF)
What this could lead to: If successful, this could offer a treatment option for hepatitis B patients with normal liver enzymes, potentially suppressing the virus and even clearing the surface antigen.
What could go wrong: This is an early-stage trial with no phase designation and only 200 participants. The drug may not work better than no treatment, and long-term safety is not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B HBV INFECTION

Contacts and locations

Locations

Beijing You'An Hospital, Capital Medical University

Beijing, China
Fuyang Second People's Hospital

Fuyang, China
Jiangsu Province Hospital

Nanjin, China
LiShui People's Hospital of Zhejiang Province

Lishui, China
People's Hospital of Dongyang City

Dongyang, China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Shanghai, China
Shanghai East Hospital

Shanghai, China
The Fifth People's Hospital of Suzhou

Suzhou, China
The Fifth People's Hospital of Wuxi

Wuxi, China
The First Affiliated Hospital of Nanchang University

Nanchang, China
The First People's Hospital of Xiaoshan District, Hangzhou, Zhejiang Province

Hangzhou, China
The Second Xiangya Hospital, Central South University

Changsha, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.